Health & Bio2 min read
Health & Bio
Novartis Heart Drug Pelacarsen Fails Pivotal Trial Despite Lowering Risk Marker
Novartis said its drug pelacarsen failed a Phase 3 trial, missing its goal of reducing cardiovascular death, heart attack or stroke, even though it sharply lowered levels of the risk marker Lp(a).
A closely watched cardiovascular drug from Novartis has failed in a pivotal study, the company said, dealing a blow to efforts to target a common heart disease risk factor. The drug, called pelacarsen, had shown in earlier trials that it could drastically lower levels of Lp(a), a blob of lipids and proteins that raises the likelihood of severe heart problems when found at elevated concentrations.
In the , called HORIZON, pelacarsen failed to reduce the risk of cardiovascular death or emergencies such as heart attacks or strokes compared with a placebo, Novartis said. The result is a setback for the broader effort to treat heart disease by targeting Lp(a) specifically, an approach that other companies, including Amgen and Eli Lilly, are also pursuing with their own experimental therapies.
Terms explained
The story so far
- Blood Thinners Cut Major Complications by 69% in Atrial Fibrillation Trial
- Children of Centenarians Have a 42% Lower Risk of Death, Study Finds
- Scientists Find a Way to Weaken Pancreatic Cancer's Protective Shield
- AstraZeneca's Breast Cancer Pill Fails Key Trial as First-Line Therapy
- Zipalertinib Plus Chemotherapy Nearly Doubles Progression-Free Time in Lung Cancer Trial
- Definium's LSD Therapy Eases Anxiety in Second Late-Stage Trial
- Novartis Heart Drug Pelacarsen Fails Pivotal Trial Despite Lowering Risk Marker
#Novartis#cardiovascular disease#clinical trial#Lp(a)#pelacarsen
Rate this story